Loblaw, a major grocery retailer, posted increased profits in the second quarter driven by strong performance at its discount chains No Frills and Maxi, along with robust sales growth in its pharmacy unit. The company, headquartered in Brampton, Ont., released its financial results for the quarter ending June 20, reporting revenue exceeding $15.3 billion, up approximately four percent from the previous quarter. Profits available to common shareholders rose by around five percent to $751 million.
Loblaw noted a 1.6 percent increase in same-store sales for its core retail food business, while its drug retail unit, which includes Shoppers Drug Mart, saw a 4.6 percent growth in same-store sales. This growth was primarily fueled by a 7.5 percent increase in pharmacy and health-care services sales. The company attributed this success partially to the increasing popularity of generic GLP-1 weight loss drugs in its pharmacy division.
According to Chief Financial Officer Richard Dufresne, the company is witnessing positive early signs from the impact of generic GLP-1 drugs, anticipating higher revenues and profits despite lower pricing. The GLP-1 drug category, which includes brands like Ozemic and Wegovy, has seen a significant uptick in sales, up by 40 percent year-to-date.
CEO Per Bank highlighted a shift in consumer behavior towards purchasing frozen vegetables over fresh produce due to rising inflation, particularly noting a 45.2 percent increase in fresh tomato prices. Customers at No Frills and Maxi stores are increasingly opting for frozen vegetables to combat inflation, with frozen veg sales growing over five percentage points in the hard discount banner.
Loblaw remains optimistic about its positioning in the market, with continued emphasis on value for customers amidst food price inflation. The company’s internal food inflation metrics are lower than the national grocery CPI, reflecting its ability to offer competitive prices. Despite the challenging economic environment, Loblaw shares traded steadily on Thursday, showing a year-to-date gain of approximately six percent.
